Transient Myeloproliferative Disorder (TMD) is a rare diagnosis that clinicians should be aware of as early recognition and management is vital. There is little guidance regarding the details of management for TMD, with respect to dosing and duration of chemotherapy. We present our management in two cases of TMD.